Literature DB >> 17593080

Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.

K Lindemann1, J Resau, J Nährig, E Kort, B Leeser, K Annecke, A Welk, J Schäfer, G F Vande Woude, E Lengyel, N Harbeck.   

Abstract

AIMS: Tyrosine kinase receptors Her2/neu and c-Met play an important role in breast cancer development and progression. Our aim was to determine the expression of c-Met, its ligand hepatocyte growth factor/scatter factor (HGF/SF) and Her2/neu in ductal carcinoma in situ (DCIS) lesions of the breast (n = 39) by two different immunocytochemical techniques, classical immunohistochemistry and immunofluorescence, and to correlate their expression levels with histopathological and clinical characteristics. METHODS AND
RESULTS: Both methods revealed similar c-Met staining patterns in both the in situ component and the adjacent normal tissue (P < 0.001). However, an imbalance in c-Met expression between tumour and surrounding normal tissue was correlated with high-grade DCIS (Van Nuys Grade 3). No correlation existed between Her2/neu and c-Met expression. High HGF/SF immunoreactivity was observed in 43.6% of the cases, yet the adjacent cellular stroma revealed only low levels of HGF/SF. No correlation existed between c-Met, Her2/neu or HGF/SF expression and clinicopathological factors.
CONCLUSION: An imbalance in c-Met expression between tumour and surrounding normal tissue is associated with an aggressive DCIS phenotype. Moreover, c-Met and HGF/SF may contribute to tumour development by different means than those controlled by Her2/neu.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593080     DOI: 10.1111/j.1365-2559.2007.02732.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  20 in total

1.  HER2 Signaling in Breast Cancer.

Authors:  Incheol Shin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Authors:  Carrie R Graveel; Jack D DeGroot; Yanli Su; Julie Koeman; Karl Dykema; Samuel Leung; Jacqueline Snider; Sherri R Davies; Pamela J Swiatek; Sandra Cottingham; Mark A Watson; Matthew J Ellis; Robert E Sigler; Kyle A Furge; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-30       Impact factor: 11.205

3.  cMET and phospho-cMET protein levels in breast cancers and survival outcomes.

Authors:  Kanwal P Raghav; Wenting Wang; Shuying Liu; Mariana Chavez-MacGregor; Xiaolong Meng; Gabriel N Hortobagyi; Gordon B Mills; Funda Meric-Bernstam; George R Blumenschein; Ana M Gonzalez-Angulo
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

4.  Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging.

Authors:  Jeroen F Vermeulen; Elsken van der Wall; Arjen J Witkamp; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2013-06-07       Impact factor: 6.730

Review 5.  Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.

Authors:  Ishwaria M Subbiah; Ana Maria Gonzalez-Angulo
Journal:  Curr Treat Options Oncol       Date:  2014-03

Review 6.  The Met oncogene and basal-like breast cancer: another culprit to watch out for?

Authors:  Stefania Gastaldi; Paolo M Comoglio; Livio Trusolino
Journal:  Breast Cancer Res       Date:  2010-08-23       Impact factor: 6.466

7.  Distinct gene-expression profiles characterize mammary tumors developed in transgenic mice expressing constitutively active and C-terminally truncated variants of STAT5.

Authors:  Tali Eilon; Itamar Barash
Journal:  BMC Genomics       Date:  2009-05-18       Impact factor: 3.969

Review 8.  Role of trastuzumab in the management of HER2-positive metastatic breast cancer.

Authors:  Andrea Milani; Filippo Montemurro; Luisa Gioeni; Massimo Aglietta; Giorgio Valabrega
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-11-24

Review 9.  MET deregulation in breast cancer.

Authors:  Gabriele Minuti; Lorenza Landi
Journal:  Ann Transl Med       Date:  2015-08

10.  Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation.

Authors:  Deeba N Syed; Farrukh Afaq; Sami Sarfaraz; Naghma Khan; Rajendra Kedlaya; Vijayasaradhi Setaluri; Hasan Mukhtar
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-09       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.